ReviewEuropean journal of clinical pharmacology2010
The pharmacological treatment of opioid addiction--a clinical perspective.
Review in European journal of clinical pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Methadone at tapered doses for the management of opioid withdrawal.The Cochrane database of systematic reviews · 2013Pooled it
- Slow-release oral morphine for opioid maintenance treatment: a systematic review.British journal of clinical pharmacology · 2011Pooled it
- Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia.Drug and alcohol dependence · 2013Trial
- Change in substance use among patients in opioid maintenance treatment: baseline to 1-year follow-up.Harm reduction journal · 2024Article
- Mini-review: The neurobiology of treating substance use disorders with classical psychedelics.Frontiers in neuroscience · 2023Review
- Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids.Journal of personalized medicine · 2022Review
- Review
- Toward evaluation of disseminated effects of medications for opioid use disorder within provider-based clusters using routinely-collected health data.Statistics in medicine · 2022Article
- The Inclusion of Patients' Reported Outcomes to Inform Treatment Effectiveness Measures in Opioid Use Disorder. A Systematic Review.Patient related outcome measures · 2022Review
- Perceived social support in patients with chronic pain with and without opioid use disorder and role of medication for opioid use disorder.Drug and alcohol dependence · 2021Article
- The Possible Relationship between the Abuse of Tobacco, Opioid, or Alcohol with COVID-19.Healthcare (Basel, Switzerland) · 2020Review
- Mass Spectrometric Imaging of the Brain Demonstrates the Regional Displacement of 6-Monoacetylmorphine by Naloxone.ACS omega · 2020Article
- Medication assisted treatment (MAT) in criminal justice settings as a double-edged sword: balancing novel addiction treatments and voluntary participation.Health & justice · 2020Article
- Pharmacological Characterization of Orofacial Nociception in Female Rats Following Nitroglycerin Administration.Frontiers in pharmacology · 2020Article
- Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.Neuropharmacology · 2019Review
- Helpful Ingredients in the Treatment of Long-Term Substance Use Disorders: A Collaborative Narrative Study.Substance abuse : research and treatment · 2019Article
- Why Do Those With Long-Term Substance Use Disorders Stop Abusing Substances? A Qualitative Study.Substance abuse : research and treatment · 2018Article
- Reduced dosing and liability in methadone maintenance treatment by targeting oestrogen signal for morphine addiction.Journal of cellular and molecular medicine · 2017Article
- The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use.Drug and alcohol dependence · 2017Article
- Evaluation of buprenorphine/naloxone dose and use of sedating supportive medication on treatment outcomes in veterans with opioid use disorder.The mental health clinician · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article reviews the main pharmacotherapies that are currently being used to treat opioid addiction. Treatments include detoxification using tapered methadone, buprenorphine, adrenergic agonists such as clonidine and lofexidine, and forms of rapid detoxification. In opioid maintenance treatment (OMT), methadone is most widely used. OMT with buprenorphine, buprenorphine-naloxone combination, or other opioid agonists is also discussed. The use of the opioid antagonists naloxone (for the treatment of intoxication and overdose) and oral and sustained-release formulations of naltrexone (for relapse prevention) is also considered. Although recent advances in the neurobiology of addictions may lead to the development of new pharmacotherapies for the treatment of addictive disorders, a major challenge lies in delivering existing treatments more effectively. Pharmacotherapy of opioid addiction alone is usually insufficient, and a complete treatment should also include effective psychosocial support or other interventions. Combining pharmacotherapies with psychosocial support strategies that are tailored to meet the patients' needs represents the best way to treat opioid addiction effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.